Nurix Therapeutics price target raised to $35 from $30 at Oppenheimer

Oppenheimer analyst Matthew Biegler raised the firm’s price target on Nurix Therapeutics to $35 from $30 and keeps an Outperform rating on the shares. The firm believes the biannual data cut from NX-5948’s ongoing Phase 1b will continue to be important for the shares and is increasingly bullish ahead of ASH. However, a fair number of investors believe the drug’s opportunity in blood cancers is baked into the current valuation, and those investors want more details on Nurix’s I&I strategy, the analyst tells investors in a research note.